ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1470

Russell Bodies and Serological Status in Rheumatoid Arthritis

Michael A. McNamara1, Susan M. Goodman2, Laura T. Donlin3, Dana Orange4, Serene Z. Mirza1, Jackie Szymonifka2, Mark P. Figgie5, Vivian P. Bykerk2 and Edward F. DiCarlo6, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, 4Rockefeller University, New York, NY, 5Surgery, Hospital for Special Surgery, New York, NY, 6Laboratory Medicine, Hospital for Special Surgery, New York, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ACPA, histopathologic, plasma cells and rheumatoid arthritis (RA), Rheumatoid Factor

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Russell Bodies and Serological Status in Rheumatoid Arthritis

Background/Purpose:

Russell bodies (RBs) are globular aggregates of immunoglobulin produced by plasma cells and identified both within the plasma cells (PCs) and free in inflamed tissues.1 It has been suggested that RBs form when antibody production surpasses protein transportation mechanisms in the cell, possibly indicating heightened production of the antibodies. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (aCCP) are antibodies commonly identified in serum of patients with rheumatoid arthritis (RA). In some patients with RA undergoing arthroplasty, synovial tissue is highly inflamed and the histologic features include the presence of plasma cells with and without RBs. The molecular features and clinical significance of RBs are unknown. Here we test the hypothesis that RBs associate with the degree of positive serology in RA.

Methods:

Tissue samples from 191 RA patients undergoing total hip, knee, shoulder, or elbow arthroplasty were scored for the proportion of PCs, the presence of binucleate plasma cells (bnPC), and RBs. Serological test results for RF and aCCP were collected. Logistic regression was used to calculate an odds ratio for positive serological results with the presence of RBs seen histologically. The concordance of bnPCs and RBs was evaluated.

Results:          

Of the 191 RA patients, 170 (89%) cases had suitable synovium for histologic characterization. Of the 170 synovial samples assessed, 37 (22%) contained RBs. Demographics (age, sex, joint replaced) of RB positive cases were similar to RB negative cases. Clinical measures (tender and swollen joint counts, patient global, and MD global) were similar between groups. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were significantly elevated in the RB-positive cohort (p<0.001). Significantly more RB-negative patients were in DAS28-ESR remission (p=0.024). RF and aCCP status were both significantly different between groups (p<0.001 and p=0.024, respectively) as well as the proportion of patients with both RF and aCCP positive results (p<0.001). The unadjusted odds ratio of having a positive serological test (RF or CCP) when RBs are found on histology is 3.94 (1.13-13.72, p=0.031). There was good concordance between bnPCs and RBs (kappa coefficient [95% CI], 0.62 [0.48 – 0.75]).

Conclusion:

The presence of RBs in synovial histology is not specifically incorporated into most synovial pathology scoring schemes. This study suggests that the presence of RBs is a significant histological finding that parallels serological status in RA, perhaps in patients with undiagnosed or untreated disease. Additionally, the association of RBs and bnPC may suggest a mechanistic connection that stands to be further explored.

References:

1. Blom J, Mansa B, Wiik A. Acta Pathologica Microbiologica Scandinavica. 1976 84A: 335-349.


Disclosure: M. A. McNamara, None; S. M. Goodman, Roche, Novartis, 4; L. T. Donlin, None; D. Orange, None; S. Z. Mirza, None; J. Szymonifka, None; M. P. Figgie, None; V. P. Bykerk, None; E. F. DiCarlo, None.

To cite this abstract in AMA style:

McNamara MA, Goodman SM, Donlin LT, Orange D, Mirza SZ, Szymonifka J, Figgie MP, Bykerk VP, DiCarlo EF. Russell Bodies and Serological Status in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/russell-bodies-and-serological-status-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/russell-bodies-and-serological-status-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology